AUTHORS
Arjun Pandey, MD, Kim Roos, HBSc2, Kathryn Mangoff, MSc3, George Tomlinson, PhD4, Gail Klein, MSc5, Diego Villa, MD6, David Macdonald, MD7, Mohammed Aljama, MD8, Mona Shafey, MD9, Nicholas Forward, MD10, Jean-Francois Larouche, MD11, Anna Nikonova, MD, FRCPC12, Michael Sebag, MD, PhD13, Irwindeep Sandhu, MD, FRCPC14, Rebecca McClure, MD15, Heidi Simmons, PhD16, Monica Gallucci17, Signy Chow, MD, FRCPC18, Neil L. Berinstein, MD19
AFFILIATIONS
1 University of Toronto, Toronto, Ontario, Canada
2 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
3 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
4 University Health Network, Toronto, Ontario, Canada
5 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
6 BC Cancer, Vancouver, British Columbia, Canada
7 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
8 Juravinski Cancer Centre, Hamilton, Ontario, Canada
9 Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
10 Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
11 CHU de Quebec-Université Laval, Québec, Quebec, Canada
12 McGill University Health Centre, Montréal, Quebec, Canada
13 McGill University Health Centre, Montréal, Quebec, Canada
14 Cross Cancer Institute, Edmonton, Alberta, Canada
15 Health Sciences North, Sudbury, Ontario, Canada
16 Adaptive Biotechnologies, Seattle, Washington, United States
17 Adaptive Biotechnologies, Seattle, Washington, United States
18 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
19 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
ABSTRACT
Introduction: The BRAWM combination regimen (bendamustine, rituximab (BR), and acalabrutinib) is associated with excellent clinical outcomes and favorable toxicity profile in patients with Waldenström’s macroglobulinemia (WM). In this analysis of the BRAWM trial, we evaluated the relationship between peripheral blood (PB) and bone marrow (BM) Measurable Residual Disease (MRD) undetectability with clinical response and outcomes in WM patients.
Methods: This multicenter phase II trial enrolled treatment-naïve WM participants who received six 28-day cycles of BR with acalabrutinib followed by fixed-duration acalabrutinib monotherapy to complete 12 months. The primary endpoint was the combined complete response and very good partial response rate (CR+VGPR) at any response time point during the first 18 months of the trial using IWWM6 criteria. MRD was assessed via next-generation sequencing (clonoSEQ®) in PB and BM at predefined intervals (Cycle 7, Cycle 12, Month 18) with a sensitivity threshold of 10-6.
Results: Median age of the 63 participants was 69 (IQR 10); 22% of participants were female. The median follow-up was 30.4 months (range 2.3 to 55.0). Baseline cancer clonotypic sequences were available/obtained in 57 participants for PB and 52 for BM. PB MRD at Cycle 7 was undetectable in 78.2%, detectable in 18.2% and indeterminate in 3.6% of participants respectively whereas for BM, MRD at Cycle 7 was undetectable in 5.5%, detectable in 89.1% and indeterminate in 5.5% of participants at a threshold of 10-6. 11/11 patients who were PB MRD detectable/indeterminate were concordantly BM MRD detectable/indeterminate at Cycle 7, whereas only 3/43 (7.0%) patients who were PB MRD undetectable were concordantly BM MRD undetectable with the remaining 40 (93.0%) discordantly BM MRD detectable/indeterminate. Throughout the follow-up period, 31/43 (72.1%) patients who were initially PB MRD undetectable at Cycle 7 remained PB MRD undetectable while 12 (27.9%) would go on to become PB MRD detectable at a threshold of 10-6. Three of these 12 had clinical progression. Of those who were initially BM MRD undetectable at Cycle 7, all 3/3 remained BM MRD undetectable throughout follow-up; by Month 18, 40/43 (93.0%) participants who were initially BM MRD detectable remained BM MRD detectable throughout all follow-up assessments as well.
The primary endpoint (CR+VGPR) was similar irrespective of Cycle 7 PB MRD status, achieved in 30/43 (69.8%) of those who were MRD undetectable and 10/12 (83.3%) of those who were MRD detectable/indeterminate. Absolute and percentage change in IgM and hemoglobin at Cycle 7, Cycle 12 and Month 18 compared with pre-treatment were similar between those who were PB MRD undetectable and PB MRD detectable/indeterminate at Cycle 7. Rate of clinical progression was very low (n=6) at a median follow-up of 28.5 months, occurring in 5/43 (11.6%) of those who were PB MRD undetectable at Cycle 7 at a median of 30.8 months (3 of whom had PB MRD relapse later in the study), compared with 1/12 (8.3%) who were Cycle 7 PB MRD detectable/indeterminate. Mortality occurred in 2/43 (4.6%; only one death was disease-specific) of those who were PB MRD undetectable at Cycle 7 and 0/12 who were MRD detectable/indeterminate.
Conclusion: PB MRD using next-generation sequencing at a sensitivity threshold of 10-6 was not strongly associated with BM MRD status or clinical objective response. With only six progression events, there was no apparent correlation between clinical progression and early PB MRD status at Cycle 7 although participants who were initially PB MRD undetectable and subsequently later had detectable PB MRD may be more likely to have clinical progression. The BRAWM regimen was associated with excellent clinical objective response rates irrespective of PB or BM MRD status.
DISCLOSURES
Arjun Pandey, MD: No relevant conflicts of interest to declare.